MX2024002566A - Regimen de dosificacion para un inhibidor de tead. - Google Patents
Regimen de dosificacion para un inhibidor de tead.Info
- Publication number
- MX2024002566A MX2024002566A MX2024002566A MX2024002566A MX2024002566A MX 2024002566 A MX2024002566 A MX 2024002566A MX 2024002566 A MX2024002566 A MX 2024002566A MX 2024002566 A MX2024002566 A MX 2024002566A MX 2024002566 A MX2024002566 A MX 2024002566A
- Authority
- MX
- Mexico
- Prior art keywords
- dosing regimen
- tead
- inhibitor
- tead inhibitor
- treatment
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163239506P | 2021-09-01 | 2021-09-01 | |
| PCT/IB2022/058130 WO2023031798A1 (en) | 2021-09-01 | 2022-08-30 | Dosing regimen for a tead inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024002566A true MX2024002566A (es) | 2024-03-20 |
Family
ID=83355146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024002566A MX2024002566A (es) | 2021-09-01 | 2022-08-30 | Regimen de dosificacion para un inhibidor de tead. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240358720A1 (https=) |
| EP (1) | EP4395768A1 (https=) |
| JP (1) | JP2024532325A (https=) |
| KR (1) | KR20240055021A (https=) |
| CN (1) | CN117835977A (https=) |
| AU (1) | AU2022340987A1 (https=) |
| CA (1) | CA3225444A1 (https=) |
| IL (1) | IL309246A (https=) |
| MX (1) | MX2024002566A (https=) |
| TW (1) | TW202327579A (https=) |
| WO (1) | WO2023031798A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119968359A (zh) | 2022-09-29 | 2025-05-09 | 英矽智能科技知识产权有限公司 | Tead抑制剂及其使用方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3156404A1 (en) * | 2015-10-15 | 2017-04-19 | Inventiva | New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma |
| CA3142351A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| EP4030233B1 (en) | 2019-09-18 | 2025-05-07 | Ningbo Sunny Opotech Co., Ltd. | Periscopic camera module and electronic device |
| UY39129A (es) | 2020-03-16 | 2021-10-29 | Novartis Ag | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead |
| CA3205726A1 (en) | 2021-01-25 | 2022-07-28 | Alfredo C. Castro | Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer |
-
2022
- 2022-08-30 US US18/687,599 patent/US20240358720A1/en active Pending
- 2022-08-30 IL IL309246A patent/IL309246A/en unknown
- 2022-08-30 WO PCT/IB2022/058130 patent/WO2023031798A1/en not_active Ceased
- 2022-08-30 CN CN202280057415.5A patent/CN117835977A/zh active Pending
- 2022-08-30 MX MX2024002566A patent/MX2024002566A/es unknown
- 2022-08-30 CA CA3225444A patent/CA3225444A1/en active Pending
- 2022-08-30 EP EP22772596.7A patent/EP4395768A1/en active Pending
- 2022-08-30 KR KR1020247009905A patent/KR20240055021A/ko active Pending
- 2022-08-30 JP JP2024512986A patent/JP2024532325A/ja active Pending
- 2022-08-30 AU AU2022340987A patent/AU2022340987A1/en active Pending
- 2022-09-01 TW TW111133168A patent/TW202327579A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL309246A (en) | 2024-02-01 |
| US20240358720A1 (en) | 2024-10-31 |
| EP4395768A1 (en) | 2024-07-10 |
| JP2024532325A (ja) | 2024-09-05 |
| WO2023031798A1 (en) | 2023-03-09 |
| KR20240055021A (ko) | 2024-04-26 |
| CN117835977A (zh) | 2024-04-05 |
| AU2022340987A1 (en) | 2024-01-18 |
| CA3225444A1 (en) | 2023-03-09 |
| TW202327579A (zh) | 2023-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025000105A (es) | Inhibidor de kras g12c para el tratamiento del cancer | |
| FI3788047T3 (fi) | Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi | |
| MX2025005489A (es) | Uso de lumateperona para el tratamiento del trastorno bipolar ii | |
| EP4272818A3 (en) | Thrombolytic agent for the treatment of thromboembolism | |
| PH12020551597A1 (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
| PH12021550302A1 (en) | Methods for the administration of certain vmat2 inhibitors | |
| ZA202209896B (en) | Sulfonamide or sulfinamide compound having effect of inducing brd4 protein degradation and pharmaceutical use thereof | |
| FI3493812T3 (fi) | Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten | |
| ZA202401684B (en) | Novel parp7 inhibitor and use thereof | |
| TN2022000113A1 (en) | Dosing regimen for anti-dll3 agents | |
| MX2024011249A (es) | Dosificacion no lineal de mirdametinib. | |
| ZA202210640B (en) | Deuterated oxophenylarsine compound and use thereof | |
| ZA202406651B (en) | Pharmaceutical composition comprising anti-ctla4-anti-pd-1 bispecific antibody and chiauranib | |
| JOP20240269A1 (ar) | حلقات كبيرة من إندازول و استخدامها | |
| MX2024002566A (es) | Regimen de dosificacion para un inhibidor de tead. | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| CL2025002930A1 (es) | Programa de dosificación de un inhibidor de her.2 | |
| WO2020243273A3 (en) | Methods of treating cholangiocarcinoma | |
| MX2023014898A (es) | Terapia combinada anti-vhc ventajosa. | |
| MX2023010545A (es) | Inhibidores de integrinas alfa v beta 6 y alfa v beta 1 y usos de los mismos. | |
| MX2025007170A (es) | Esquema de dosificacion de una dispersion solida de un inhibidor de her2 | |
| TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. | |
| ATE298240T1 (de) | Getrennte dosis therapien mit gefässschädigender aktivität | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| MX2025010543A (es) | Composiciones que comprenden 5-metoxi-2-aminoindan para el tratamiento de la depresion |